Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S, Madsen HO, Siitonen SM, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: tierens a. Leukemia. 2019 Jun;33(6):1324-1336. doi: 10.1038/s41375-018-0307-6. Epub 2018 Dec 14. Leukemia. 2019. PMID: 30552401
Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment.
Björklund E, Matinlauri I, Tierens A, Axelsson S, Forestier E, Jacobsson S, Ahlberg AJ, Kauric G, Mäntymaa P, Osnes L, Penttilä TL, Marquart H, Savolainen ER, Siitonen S, Torikka K, Mazur J, Porwit A. Björklund E, et al. Among authors: tierens a. J Pediatr Hematol Oncol. 2009 Jun;31(6):406-15. doi: 10.1097/MPH.0b013e3181a1c0e8. J Pediatr Hematol Oncol. 2009. PMID: 19648789
Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.
Tierens A, Bjørklund E, Siitonen S, Marquart HV, Wulff-Juergensen G, Pelliniemi TT, Forestier E, Hasle H, Jahnukainen K, Lausen B, Jonsson OG, Palle J, Zeller B, Fogelstrand L, Abrahamsson J. Tierens A, et al. Br J Haematol. 2016 Aug;174(4):600-9. doi: 10.1111/bjh.14093. Epub 2016 Apr 13. Br J Haematol. 2016. PMID: 27072379 Free article.
Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.
Karlsson L, Forestier E, Hasle H, Jahnukainen K, Jónsson ÓG, Lausen B, Norén Nyström U, Palle J, Tierens A, Zeller B, Abrahamsson J. Karlsson L, et al. Among authors: tierens a. Br J Haematol. 2017 Aug;178(4):592-602. doi: 10.1111/bjh.14720. Epub 2017 Apr 25. Br J Haematol. 2017. PMID: 28439893 Free article. Clinical Trial.
Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
Delsing Malmberg E, Rehammar A, Pereira MB, Abrahamsson J, Samuelsson T, Ståhlman S, Asp J, Tierens A, Palmqvist L, Kristiansson E, Fogelstrand L. Delsing Malmberg E, et al. Among authors: tierens a. J Mol Diagn. 2019 Jan;21(1):149-162. doi: 10.1016/j.jmoldx.2018.08.004. Epub 2018 Sep 29. J Mol Diagn. 2019. PMID: 30273780 Free article.
Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S, Madsen HO, Siitonen SM, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: tierens a. Leukemia. 2020 Jun;34(6):1719-1720. doi: 10.1038/s41375-019-0672-9. Leukemia. 2020. PMID: 31822778
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.
Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, Fagerli UM, Larsen TS, Mannisto S, Munksgaard L, Maisenhölder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Liestøl K, Ralfkiaer E, Spetalen S, Beiske K, Karjalainen-Lindsberg ML, Holte H. Leppä S, et al. Among authors: tierens a. Blood Adv. 2020 May 12;4(9):1906-1915. doi: 10.1182/bloodadvances.2020001518. Blood Adv. 2020. PMID: 32380536 Free PMC article. Clinical Trial.
100 results